Diabetes and Hypertension among Patients Receiving Antiretroviral Treatment Since 1998 in Senegal: Prevalence and Associated Factors

Table 4

Multiple regression analyses for factors associated with diabetes and hypertension.

Characteristics	Diabetes		Hypertension
	OR	95% CI	OR	95% CI
ART duration, months			0.99	0.96–1.01
Short < 119	1
Long ≥ 119	3.78	1.69–8.42
Age, years	1.06	1.01–1.11	1.06	1.02–1.10
Sex
Male			1
Female			0.83	0.41–1.69
BMI, kg/m²			1.10	1.03–1.18
BMI at treatment initiation, kg/m²	1.13	1.02–1.26	1.07	0.95–1.19
CD4 cell count, cells/μL			1.00	0.98–1.02
Total cholesterol (g/L)	1.78	0.68–4.66	2.48	1.19–5.16
Triglycerides (g/L)	2.32	1.12–4.81	1.34	0.67–2.69
Drug exposure duration (months)
Zidovudine (AZT)	1.05	0.97–1.13
Stavudine (d4T)	1.06	0.99–1.15	1.01	0.95–1.08
Didanosine (ddI)	0.98	0.90–1.06
Nevirapine (NVP)	0.99	0.92–1.06
Indinavir (IDV)	1.03	0.95–1.13	1.10	1.03–1.16
Lopinavir/ritonavir (LPV/r)	0.84	0.67–1.05	0.84	0.71–0.99

OR: odds-ratio; CI: confidence interval; BMI: body mass index; HCV: hepatitis C virus; HBV: hepatitis B virus.